Kyntra Bio (KYNB) Q2 2026 Earnings Report

The call presented multiple meaningful clinical and operational positives: concrete Phase I/IST efficacy signals for FG-3246 (with a clear plan for a Phase II interim readout in Q4 2026), a finalized Phase III protocol and compelling subgroup data for roxadustat, a unique non-PSMA therapeutic + companion diagnostic position, and a positive swing to net income with a cash runway into 2028. Offsetting these were notable near-term financial headwinds (negative reported revenue and higher operating expenses), safety and biomarker confirmation risks that require larger data sets, enrollment and market dynamics uncertainty (Pluvicto adoption) and the dependence on partnering/capital for a registrational path for roxadustat. On balance, the highlights modestly outweigh the lowlights due to actionable clinical progress and a forthcoming near-term catalyst (FG-3246 interim) alongside sufficient cash runway to advance programs.

The company reiterated specific near-term clinical and financial guidance: as of June 30, 2026 Kyntra reported $95.7M in cash/equivalents/investments/accounts receivable and expects a cash runway into 2028; Q2 2026 revenue was -$1.5M (vs $1.3M prior), operating expenses $16.1M (vs $13.4M), R&D $6.8M (vs $5.9M), SG&A $9.3M (vs $7.1M), and net income from continuing operations was $12.0M or $2.96/share (vs a $13.7M loss, $3.38/share a year ago). Clinical milestones: FG‑3246/FG‑3180 phase II is enrolling 75 post‑ARPI pre‑chemo mCRPC patients across three dose levels (1.8/2.4/2.7 mg/kg) with G‑CSF prophylaxis at 23 live U.S. sites, an interim analysis of 36 patients on track for Q4 2026 (PSA50, ORR, safety, PK, exposure‑response; futility by composite PSA50+ORR), and mature rPFS data expected through 2027 (goal: improve on the phase I median rPFS of 8.7 months and target ≥10 months; phase I: PSA50 36%, ORR 20% of 25 RECIST‑evaluable, DOR 7.5 months at 2.7 mg/kg; IST combo: median rPFS 7.0 months overall and 10.1 months in patients with one prior ARPI; higher FG‑3180 SUV trended with greater PSA50). For roxadustat, the phase III protocol is finalized with a primary endpoint of 8‑week transfusion independence over the first 24 weeks (key secondaries: 12/16/24‑week TI over 48 weeks), a goal to initiate the registrational trial in Q4 2026, dosing to start at 2.5 mg/kg with titration up to 3.5 mg/kg in staged intervals (dose changes possible every ~6 weeks), MATTERHORN post‑hoc high‑transfusion‑burden results showed 36% vs 7% achieving ≥8‑week TI (nominal p=0.041), the program has Orphan Drug status, will enroll RS+ and RS‑ patients, and Kyntra is weighing internal development (would owe AZ a mid‑single‑digit royalty) versus partnering (AZ would receive 35% of economics to Kyntra).